Louis Fries Selected Research

Matrix-M

12/2023	The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century.
1/2023	Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
12/2022	Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
12/2021	Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
1/2021	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
1/2021	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Louis Fries Research Topics

Disease

13	Human Influenza (Influenza) 11/2022 - 01/2006
9	COVID-19 12/2023 - 12/2020
2	Virus Diseases (Viral Diseases) 01/2024 - 01/2021
2	Infections 01/2023 - 08/2014
2	Malaria 12/2022 - 01/2021
1	Asymptomatic Diseases 01/2023
1	Hypoxia (Hypoxemia) 01/2023
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2023
1	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2021
1	Influenza in Birds (Avian Flu) 07/2015
1	Anaphylaxis (Anaphylactic Shock) 08/2011
1	Injection Site Reaction 06/2011
1	Pain (Aches) 06/2011
1	Rhinorrhea 01/2006

Drug/Important Bio-Agent (IBA)

21	VaccinesIBA 07/2023 - 01/2006
7	NVX-CoV2373 adjuvated lipid nanoparticleIBA 12/2023 - 12/2020
7	AntigensIBA 01/2021 - 01/2006
6	Matrix-MIBA 12/2023 - 01/2021
5	Immunoglobulin G (IgG)IBA 01/2024 - 12/2020
5	AntibodiesIBA 01/2023 - 01/2006
5	Influenza Vaccines (Influenza Vaccine)FDA Link 08/2014 - 01/2006
3	Proteins (Proteins, Gene)FDA Link 07/2023 - 01/2021
2	Recombinant ProteinsIBA 01/2023 - 01/2023
2	AS03 adjuvantIBA 01/2013 - 08/2011
1	Messenger RNA (mRNA)IBA 01/2024
1	SaponinsIBA 12/2023
1	Subunit VaccinesIBA 12/2023
1	Biomarkers (Surrogate Marker)IBA 02/2023
1	Glycoproteins (Glycoprotein)IBA 01/2023
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2023
1	Nucleocapsid ProteinsIBA 01/2023
1	Neutralizing AntibodiesIBA 01/2023
1	Rabies Vaccines (Rabies Vaccine)FDA Link 12/2022
1	rabivaxIBA 12/2022
1	asparaginyl-prolineIBA 01/2021
1	NanovaccinesIBA 01/2018
1	EpitopesIBA 07/2015
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2014
1	Bacterial Outer Membrane ProteinsIBA 03/2011
1	Detergents (Detergent)IBA 03/2011
1	fluarixIBA 11/2008
1	FluLavalIBA 11/2008
1	Membrane Proteins (Integral Membrane Proteins)IBA 03/2006
1	Secretory Immunoglobulin A (SIgA)IBA 01/2006

Therapy/Procedure

1	Intranasal Administration 01/2006